GLP-1 medications have rapidly become some of the most influential treatments for Type 2 diabetes and weight loss. As more people look into these prescriptions, there is growing curiosity about how ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors.

This article originally appeared on PolitiFact. If you watch TV and don't mute ads, you've probably heard of a few biologics. They're drugs such as Humira for arthritis and Trulicity for Type 2 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 use appears to be rising among patients with MASH ...

Weight-loss surgery dramatically outperformed GLP-1 medications in improving longevity and reducing heart, kidney, and eye complications for people with obesity and diabetes. Over 10 years, patients ...

Most students expect to see one professor at the front of the classroom throughout the semester. But for those attending Harvey Mudd College, a STEM-focused institution in California, it’s not unusual ...

The global GLP-1 market has been in the spotlight for the past couple of years as big pharma players realize its multi-billion-dollar potential and the untapped nature. It is currently dominated by ...

Novo Nordisk A/S rose the most in a month after its diabetes blockbuster Ozempic beat Eli Lilly & Co.’s older drug Trulicity in a real-world survey of certain US patients. Medicare patients who took ...

The duel of the GLP-1 data sets continues this week, with Novo issuing the latest salvo of updates on its oral obesity candidate and an Ozempic head-to-head trial win against another stalwart diabetes ...

The World Health Organization added Novo Nordisk A/S’s Ozempic and Eli Lilly and Co.’s Mounjaro to its list of essential medicines, a step that may expand access to the drugs around the world. The ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Eli Lilly (NYSE:LLY) has quickly emerged as one of Wall ...